

In the Claims


Please cancel claims 1-6 without prejudice.

Please rewrite Claim 7 as follows:


7
Q2
B3
(Once amended) An angiogenesis inhibitory composition comprising an angiogenesis inhibiting compound and an anti-inflammatory drug,
wherein the angiogenesis inhibiting compound is selected from the group consisting of:

(1) a compound selected from the formula

A)




B)



or

C)




wherein

Red B3
Green A2
Orange C1

R₁ - R₄ are each independently selected from H; OH; =O; straight or branched chain alkanes, alkenes, and alkynes; cyclic alkanes, alkenes, and alkynes; combinations of cyclic and acyclic alkanes, alkenes, and alkynes; alcohol, aldehyde, ketone, carboxylic acid, ester, or ether moieties in combination with acyclic, cyclic, or combination acyclic/cyclic moieties; aza; amino; -XO_n or -O-XO_n, where X=N and n=2, X=S and n=2 or 3, or X=P and n=1-3; and halogens;


R₅ - R₈ are each independently selected from




or -O-, where Y is absent and R₁₀ is =O or Y and R₁₀ are each independently the same as R₁;

and R₉ is a moiety selected from the group consisting of


D)



E)




F)




and
B
Some

and
and

G)



and H)




wherein each of R₁₁ - R₁₇ is independently the same as R₅, and wherein R₁₈, R₁₉ and R₂₀ are each independently selected from

H, CH₃, -C(=O)-OH, -C(=O)-NH₂, -(CH₂)_n-C(=O)-OH, and -(CH₂)_n-C(=O)-NH₂,


and n=1 through 4;

(2) a compound selected from the formula



where R₂₂ and R₂₃ are each independently H, F, Cl, Br, I, CH₃, or -CH₂-CH₃;
and R₂₄ is H, CH₃, or -CH₂-CH₃;
and

(3) a compound selected from the formula



where X is R₆ as defined in (1) above.

Please add the following new claims:

9. 21. (New Claim) The angiogenesis inhibitory composition of Claim 7 wherein the antiinflammatory drug is a steroid.

10. 22. (New Claim) The angiogenesis inhibitory composition of Claim 21 wherein the steroid is selected from the group consisting of cortisol, corticosterone, hydrocortisone, hydrocortisol, cortisone, prednisone, prednisolone, dexamethasone, beclomethasone, betamethasone, mometasone, mometasone furoate, budesonide, triamcinolone acetonide and fluticasone.

11. 23. (New Claim) An angiogenesis inhibitory composition of Claim 7 wherein the anti-inflammatory drug is a nonsteroidal, anti-inflammatory drug (NSAID).

12. 24. (New Claim) The angiogenesis inhibitory composition of Claim 23 wherein the NSAID is selected from aspirin, acetominophen, ibuprofen, esculetin, phenidone, quercetin, ketoprofen, nordihydroguaiaretic acid (NDGA), sulindac, sulindac sulfone, sulindac sulfide, indomethacin, NS-398 (a cyclooxygenase-2 inhibitor), cyclooxygenase-1 inhibitors, methylheptyl imidazole, furegrelate sodium, SKF525AHCL, thromboxane inhibitors, toradol, ecasa, salsalate, diflunisal, mefenamic acid, naproxen, naproxen sodium, floctafenine, meclofenamate, phenylbutazone, oxyphenbutazone, diclofenac, etodolac, fenoprofen, flufenamic acid, flurbiprofen, pirprofen, tolmetin, apazone, fenbufen, nabumetone, oxaprozin, piroxicam, salicylate, and tenoxicam.


13. 25. (New Claim) The angiogenesis inhibitory composition of Claim 23 wherein the NSAID is selected from indomethacin and sulindac.

14. 26. (New Claim) A method for inhibiting angiogenesis in a human or animal comprising administering to the human or animal a composition comprising an angiogenesis inhibiting compound and an anti-inflammatory compound, wherein the angiogenesis inhibiting compound is selected from the group consisting of


*AS
Auth*

(1) a compound selected from the formula

A)




B)



or


C)



wherein

R₁ - R₄ are each independently selected from H; OH; =O; straight or branched chain alkanes, alkenes, and alkynes; cyclic alkanes, alkenes, and alkynes; combinations of cyclic and acyclic alkanes, alkenes, and alkynes; alcohol, aldehyde, ketone, carboxylic acid, ester, or ether moieties in combination with acyclic, cyclic, or combination acyclic/cyclic moieties; aza; amino; -XO_n or -O-XO_n, where X=N and n=2, X=S and n=2 or 3, or X=P and n=1-3; and halogens;

R₅ - R₈ are each independently selected from




or -O-, where Y is absent and R₁₀ is =O or Y and R₁₀ are each independently the same as R₁;

and R₉ is a moiety selected from the group consisting of


D)




E)




F)





and H)




wherein each of R₁₁ - R₁₇ is independently the same as R₅, and wherein R₁₈, R₁₉ and R₂₀ are each independently selected from

H, CH₃, -C(=O)-OH, -C(=O)-NH₂, -(CH₂)_n-C(=O)-OH, and -(CH₂)_n-C(=O)-NH₂,


and n=1 through 4;

(2) a compound selected from the formula



where R₂₂ and R₂₃ are each independently H, F, Cl, Br, I, CH₃, or -CH₂-CH₃;
and R₂₄ is H, CH₃, or -CH₂-CH₃;
and

(3) a compound selected from the formula



where X is R₆ as defined in (1) above; and


*AB
Ansley*

27. (New Claim) A method for treating an angiogenesis dependent disease in a human or animal having such a disease comprising administering to the human or animal a composition comprising an angiogenesis inhibiting compound and an antiinflammatory compound


wherein the angiogenesis inhibiting compound is selected from the group consisting of

(1) a compound selected from the formula

A)




B)



or


C)



wherein

R₁ - R₄ are each independently selected from H; OH; =O; straight or branched chain alkanes, alkenes, and alkynes; cyclic alkanes, alkenes, and alkynes; combinations of cyclic and acyclic alkanes, alkenes, and alkynes; alcohol, aldehyde, ketone, carboxylic acid, ester, or ether moieties in combination with acyclic, cyclic, or combination acyclic/cyclic moieties; aza; amino; -XO_n or -O-XO_n, where X=N and n=2, X=S and n=2 or 3, or X=P and n=1-3; and halogens;


R₅ - R₈ are each independently selected from




or -O-, where Y is absent and R₁₀ is =O or Y and R₁₀ are each independently the same as R₁;

and R₉ is a moiety selected from the group consisting of


D)




E)




F)



G)



and H)




wherein each of R₁₁ - R₁₇ is independently the same as R₅, and wherein R₁₈, R₁₉ and R₂₀ are each independently selected from

H, CH₃, -C(=O)-OH, -C(=O)-NH₂, -(CH₂)_n-C(=O)-OH, and -(CH₂)_n-C(=O)-NH₂,

and n=1 through 4;

(2) a compound selected from the formula




where R₂₂ and R₂₃ are each independently H, F, Cl, Br, I, CH₃, or -CH₂-CH₃;

and R₂₄ is H, CH₃, or -CH₂-CH₃;

and

2nd
3rd
4th
5th
6th
7th
8th
9th

(3) a compound selected from the formula



where X is R₆ as defined in (1) above.

28. (New Claim) The method of Claim 27 wherein the angiogenesis dependent disease is selected from macular degeneration, diabetic retinopathy, neovascular glaucoma, retrolental fibroplasias, proliferative vitreoretinopathy, solid tumors, blood-borne tumors, leukemia, hemangioma, psoriasis, Kaposi's sarcoma, Crohn's disease, ulcerative colitis, cancer, retinopathy of prematurity, corneal graft rejection, epidemic keratoconjunctivitis, Vitamin A deficiency, contact lens overwear, atopic keratitis, superior limbic keratitis, pterygium keratitis sicca, sjogren's syndrome, acne rosacea, phylectenulosis, syphilis, *Mycobacteria* infections, lipid degeneration, chemical burns, bacterial ulcers, fungal ulcers, *Herpes simplex* infections, *Herpes zoster* infections, Mooren's ulcer, Terrien's marginal degeneration, marginal keratolysis, trauma, rheumatoid arthritis systemic lupus, polyarteritis, Wegener's sarcoidosis, scleritis, Stevens-Johnson disease, radial keratotomy, corneal graft rejection, sickle cell anemia, pseudoxanthoma elasticum, pemphigoid, Paget's disease, vein occlusion, artery occlusion, carotid obstructive disease, chronic uveitis, chronic vitritis, Lyme's disease, systemic lupus erythematosis, Eales' disease, Behcet's disease, presumed ocular histoplasmosis, Best's disease, myopia, optic pits, Stargardt's disease, pars planitis, chronic retinal detachment, hyperviscosity syndromes, toxoplasmosis, post-laser complications, and rubeosis.

15
29. (New Claim) The angiogenesis inhibitory composition of Claim 7 wherein the dosage of the angiogenesis inhibiting compound is between about 0.1 to about 300 mg/kg/day.

16
30. (New Claim) The angiogenesis inhibitory composition of Claim 7 wherein the dosage of the angiogenesis inhibiting compound is between about 0.5 to about 50 mg/kg/day.

17 31. (New Claim) The angiogenesis inhibitory composition of Claim *7* wherein the dosage of the angiogenesis inhibiting compound is between about 1 to about 10 mg/kg/day.

24 32. (New Claim) The method of Claim *26* wherein the composition comprises a formulation suitable for oral, rectal, ophthalmic, nasal, topical, vaginal, or parenteral administration.

Sub J3 33. (New Claim) The method of Claim 22 wherein the composition comprises a formulation suitable for oral, rectal, ophthalmic, nasal, topical, vaginal, or parenteral administration.

25 34. (New Claim) The method of Claim *26* wherein the dosage of the angiogenesis inhibiting compound is between about 0.1 mg/kg/day to about 300 mg/kg/day.

26 35. (New Claim) The method of Claim *26* wherein the dosage of the angiogenesis inhibiting compound is between about 0.5 mg/kg/day to about 50 mg/kg/day.

27 36. (New Claim) The method of Claim *26* wherein the dosage of the angiogenesis inhibiting compound is between about 1 mg/kg/day to about 10 mg/kg/day.


31 37. (New Claim) The method of Claim *27* wherein the dosage of the angiogenesis inhibiting compound is between about 0.1 mg/kg/day to about 300 mg/kg/day.

32 38. (New Claim) The method of Claim *27* wherein the dosage of the angiogenesis inhibiting compound is between about 0.5 mg/kg/day to about 50 mg/kg/day.

33 39. (New Claim) The method of Claim *27* wherein the dosage of the angiogenesis inhibiting compound is between about 1 mg/kg/day to about 10 mg/kg/day.

*B
A
Amstel*

40. (New Claim) An angiogenesis inhibitory composition comprising an angiogenesis inhibiting compound and an anti-inflammatory drug, wherein the angiogenesis inhibiting compound has the formula



41. (New Claim) The angiogenesis inhibitory composition of Claim 40 wherein the antiinflammatory drug is a steroid.

42. (New Claim) The angiogenesis inhibitory composition of Claim 41 wherein the steroid is selected from the group consisting of cortisol, corticosterone, hydrocortisone, hydrocortisol, cortisone, prednisone, prednisolone, dexamethasone, beclomethasone, betamethasone, mometasone, mometasone furoate, budesonide, triamcinolone acetonide, and fluticasone.

6 43. (New Claim) An angiogenesis inhibitory composition of Claim 11
wherein the anti-inflammatory drug is a nonsteroidal, anti-inflammatory drug (NSAID). *5*

*B
8
9*

44. (New Claim) The angiogenesis inhibitory composition of Claim 43 wherein the NSAID is selected from aspirin, acetominophen, ibuprofen, esculetin, phenidone, quercetin, ketoprofen, nordihydroguaiaretic acid (NDGA), sulindac, sulindac sulfone, sulindac sulfide, indomethacin, NS-398 (a cyclooxygenase-2 inhibitor), cyclooxygenase-1 inhibitors, methylheptyl imidazole, furegrelate sodium, SKF525AHCL, thromboxane inhibitors, toradol, ecasa, salsalate, diflunisal, mefenamic acid, naproxen, naproxen sodium, floctafenine, meclofenamate, phenylbutazone, oxyphenbutazone, diclofenac, etodolac, fenoprofen, flufenamic acid, flurbiprofen, pirprofen, tolmetin apazone, fenbufen, nabumetone, oxaprozin, piroxicam, salicylate, and tenoxicam.